Results 101 to 110 of about 615,884 (310)

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

open access: yesMolecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li   +10 more
wiley   +1 more source

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. [PDF]

open access: yes, 2020
PurposeImmune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and ...
Baghdadi, Tareq Al   +21 more
core  

Development of taxane resistance in a panel of human lung cancer cell lines [PDF]

open access: yes, 2008
Using a selection process designed to reflect clinically relevant conditions, a panel of taxane-selected variants were developed to study further the mechanisms of resistance in lung cancer.
Breen, Laura   +3 more
core   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

open access: yesMolecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff   +11 more
wiley   +1 more source

Tumor suppressor miR-29c regulates radioresistance in lung cancer cells

open access: yesTumor Biology, 2017
Radiotherapy is an important treatment option for non-small cell lung carcinoma patients. Despite the appropriate use of radiotherapy, radioresistance is a biological behavior of cancer cells that limits the efficacy of this treatment.
Elena Arechaga-Ocampo   +14 more
doaj   +1 more source

A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer. [PDF]

open access: yes, 2012
Metastatic non-small cell lung cancer (NSCLC) carries a dismal prognosis. Clinical evidence suggests the existence of an intermediate, or oligometastatic, state when metastases are limited in number and/or location.
Niibe, Yuzuru   +4 more
core   +3 more sources

Neuroendocrine differentiation in non-small cell lung carcinomas.

open access: yesIn vivo (Athens, Greece), 2000
The immunohistochemical expression of ten neuroendocrine and neural differentiation-related antigens in 200 specimens from patients with surgically resected non-small cell lung carcinomas were evaluated. Poorly differentiated adenocarcinomas and undifferentiated large cell carcinomas showed the highest percentage of positive samples (30%-60%) for the ...
BALDI, Alfonso   +5 more
openaire   +2 more sources

Crizotinib in the treatment of non-small-cell lung carcinoma.

open access: yesContemporary oncology (Poznan, Poland), 2013
Recent studies have demonstrated the benefit of EGFR tyrosine kinase inhibitors in the treatment of advanced non-small-cell lung cancer (NSCLC). The role of activation of the anaplastic lymphoma kinase (ALK) pathway and the presence of the fusion gene EML4-ALK are new molecular targets in studies into the pathogenesis and treatment of NSCLC.
Płużański, Adam   +2 more
openaire   +2 more sources

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

Changes on Mitochondrial DNA Content in Non-small Cell Lung Cancer [PDF]

open access: yes, 2011
Background and objective It has been proven that the mitochondrial DNA (mtDNA) mutations and content change were associated with increasing risk of tumorigenesis. MtDNA content is significantly reduced in most substantive tumors. The aim of this study is
Hongmei WANG, Jigang DAI
core  

Home - About - Disclaimer - Privacy